Preeclampsia History Increases Risk for End-Stage Kidney Disease
WEDNESDAY, July 31, 2019 -- Women with preeclampsia have an increased risk for developing end-stage kidney disease (ESKD), according to a study published online July 30 in PLOS Medicine.
Ali S. Khashan, Ph.D., from the University College Cork in Ireland, and colleagues used data from the Swedish Medical Birth Register to examine the correlation between preeclampsia and the risk for ESKD in healthy women. Data were included for 1,366,441 healthy women with 2,665,320 singleton live births in Sweden between 1982 and 2012; participants were followed for a median of 7.4 years overall and 16.4 years among those with a diagnosis of ESKD.
The researchers found that 67,273 women (4.9 percent) with 74,648 singleton live births (2.8 percent of all pregnancies) had preeclampsia; 410 women developed ESKD (incidence rate, 1.85 per 100,000 person-years). In the unadjusted analysis, preeclampsia was associated with ESKD (hazard ratio, 4.99); in the extensively adjusted models, the correlation persisted (hazard ratio, 4.96). Compared with women with no preeclampsia, those with preterm preeclampsia and with preeclampsia in two pregnancies had the highest risk for ESKD (adjusted hazard ratios, 9.19 and 7.13, respectively).
"Preeclampsia is a sex-specific, independent risk factor for the subsequent development of ESKD. However, it should be noted that the overall ESKD risk remains small," the authors write. "Whether screening and/or preventative strategies will reduce the risk of ESKD in women with adverse pregnancy outcomes is worthy of further investigation."
Two authors disclosed financial ties to the biopharmaceutical industry.
© 2020 HealthDay. All rights reserved.
Posted: July 2019
More News Resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
- Monthly Update Archive
Subscribe to our Newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.